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Abstract 
Background: Matrix metalloproteinases (MMPs) 2 and 9 are zinc- and calcium-dependent endopeptidases involved 
in the breakdown and reconstitution of extracellular matrix under both physiological and pathological conditions. 
Mucosal MMP-2 and -9 activities have been reported to be upregulated in the intestine of humans with inflammatory 
bowel disease (IBD), and in animal models of IBD. However, their involvement in the pathogenesis of canine chronic 
enteropathies (CE) is unknown. This study investigated mucosal pro- and active MMP-2 and -9 activities in dogs with 
CE and healthy dogs using gelatin zymography, and also to determine the association of their activities in dogs with 
CE with the canine IBD activity index (CIBDAI), histopathologic findings, the clinical outcome, and hypoalbuminemia. 
Intestinal mucosal samples from duodenum, ileum, colon, and cecum were collected from 40 dogs with CE and 18 
healthy Beagle dogs.
Results: In dogs with CE, the number of samples positive for mucosal pro- and active MMP-2 was significantly 
higher in the duodenum (P < 0.0001 and P = 0.011, respectively), ileum (P = 0.002 and P = 0.018, respectively), and 
colon (P < 0.0001 and P = 0.002, respectively), compared with healthy controls. Mucosal pro-MMP-9-positive samples 
in the duodenum and colon were significantly more frequent in dogs with CE than in healthy dogs (P = 0.0004 and 
P = 0.001, respectively). Despite the presence of mucosal samples positive for active MMP-9 in the intestinal seg-
ments of dogs with CE, the difference compared to healthy controls did not reach statistical significance. None of 
the intestinal mucosal samples in healthy dogs showed gelatinolytic activity corresponding to the control bands of 
active MMP-2 and -9. Mucosal active MMP-9 activities displayed a significant positive association with the severity of 
neutrophil infiltration in the duodenum (P = 00.040), eosinophils in the cecum (P = 00.037), and the CIBDAI score for 
ileum samples (P = 0.023). There was no significant association of pro- and active MMP-2 and -9 levels with the clinical 
outcome or hypoalbuminemia.
Conclusions: This study is the first to demonstrate upregulation of mucosal pro- and active MMP-2 and pro-MMP-9 
in the intestine of dogs with CE compared to healthy dogs. The results provide supporting evidence for the possible 
involvement of MMP-2 and -9 in the pathogenesis of canine CE.
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Background
Chronic enteropathy (CE) is a term used to describe a 
group of inflammatory conditions of the intestinal tract 
of unknown cause in dogs [1]. Canine CE causes chronic 
gastrointestinal signs such as vomiting, diarrhea, tenes-
mus, hematochezia, and decreased appetite and leads to 
weight loss [1, 2]. There are different clinical types of CE 
in dogs, which are determined by their response to treat-
ment and defined as food-responsive diarrhea or enter-
opathy (FRD or FRE), antibiotic-responsive diarrhea or 
enteropathy (ARD or ARE), steroid-responsive diarrhea 
or enteropathy (SRD or SRE), or steroid-non-responsive 
diarrhea or enteropathy (SNRD or SNRE) [3, 4]. Syn-
onymous for CE, the term inflammatory bowel disease 
(IBD) has also been used in dogs, for example in a review 
determining canine IBD/CE according to the response 
to treatment [3]. While the etiology and pathophysiol-
ogy of canine CE are not fully understood, interactions 
between the mucosal immune system, the host genetic 
susceptibility, and the environment such as microbial 
antigens and dietary antigens, have been identified as 
potential causative factors in the development of chronic 
gastrointestinal inflammation [3, 5–8]. The occurrence of 
an aberrant immune response to antigens derived from 
endogenous microbiota is likely to play an important role 
in CE pathogenesis; however, the specific pathways lead-
ing to tissue injury and intestinal inflammation are not 
fully understood [3, 8, 9].
Matrix metalloproteinases (MMPs) are a group of 
zinc- and calcium-dependent endopeptidases that are 
important in the turnover of extracellular matrix (ECM) 
and cell migration [10, 11]. In addition, MMPs proteo-
lytically activate or degrade a variety of non-matrix sub-
strates, including chemokines, cytokines, growth factors, 
and junctional proteins. Therefore, they play important 
roles in inflammatory responses [10]. MMPs have been 
divided according to their domain structure and substrate 
specificity into gelatinases, collagenases, stromelysins, 
elastases, and membrane-type MMPs [12]. Gelatinases 
are composed of two members: MMP-2 (gelatinase A) 
and MMP-9 (gelatinase B), which degrade similar sub-
strates, such as gelatin, collagen types IV and V, elastin, 
laminin, fibronectin, and proteoglycans [12–14]. Both 
MMP-2 and -9 have pro and active forms with differ-
ent molecular weights. MMP-2 is primarily produced by 
stromal cells, including fibroblasts, myofibroblasts, and 
endothelial cells [15, 16]. MMP-9 is mainly produced by 
neutrophils and to a lesser extent by eosinophils, mono-
cytes, macrophages, lymphocytes, and epithelial cells 
[14, 15, 17–19]. Intestinal mucosal MMP-2 and -9 activi-
ties have been reported to be upregulated in humans 
with IBD (in both Crohn’s disease [CD] and ulcerative 
colitis [UC]), and also in animal models of human IBD 
[13–15, 20, 21]. In a mouse model of colitis, MMP-2 was 
observed to play a protective role against tissue damage, 
possibly through the regulation of epithelial barrier func-
tion [10, 13, 14]. However, in humans with IBD, it con-
tributes to ECM remodeling and the degradation of basal 
membrane type IV collagen, leading to intestinal ulcera-
tion, epithelial damage, and/or fistula formation [12, 15, 
22–24]. In both humans with IBD and animal models 
of human IBD, MMP-9 plays a crucial role in both the 
induction of intestinal inflammation and wound healing. 
It promotes neutrophil migration, increases paracellular 
permeability, and reduces the adhesion complex integrity 
of the epithelium. In addition, MMP-9 interferes with re-
epithelialization, resulting in impaired wound healing in 
cornea, skin, endothelial cells, and also in cultured intes-
tinal epithelial cells [10, 13–15, 25].
In healthy dogs, we determined mucosal MMP-2 and 
-9 activities in different intestinal segments of Beagles in 
a previous study [26]. Only inactive pro-forms of MMP-2 
and -9 were detected in the intestinal mucosa. Thus far, 
it has been unknown whether MMP-2 and -9 are also 
involved in the pathogenesis of canine CE. However, in 
dogs with CE, gene expression of MMP-1, -3, and -13 has 
been reported to be upregulated in the intestinal mucosa 
[27].
Therefore, the hypothesis of this study was that dogs 
with CE have higher MMP-2 and -9 activities in their 
intestinal mucosa than healthy dogs. The study also 
aimed at evaluating the association of intestinal mucosal 
MMP-2 and -9 activities with histological changes, the 
canine inflammatory bowel disease activity index (CIB-
DAI), the clinical outcome, and hypoalbuminemia in 
dogs with CE.
Methods
Animals
In this study, 52 dogs were included when undergo-
ing routine gastroduodenoscopy and/or colonoscopy 
at the Veterinary Teaching Hospital, Faculty of Veteri-
nary Medicine, University of Helsinki, Finland, due to 
chronic gastrointestinal (GI) signs such as vomiting, diar-
rhea, tenesmus, hematochezia, and/or weight loss. The 
study was prospectively planned and ethically approved 
by the Finnish National Animal Experiment Board 
(study license numbers: ESAVI/6973/04.10.03/2011  and 
ESAVI/10384/04.10.07/2014). Informed owner consent 
was obtained at the time the dogs were enrolled for per-
forming gastroduodenoscopy and/or colonoscopy.
As a control group, we used stored intestinal tissue 
samples taken from 18 healthy laboratory Beagle dogs 
that underwent post-mortem examinations when finish-
ing other unrelated studies. These studies were approved 
by the Finnish National Animal Experiment Board (study 
Page 3 of 10Hanifeh et al. Acta Vet Scand  (2018) 60:16 
license numbers: ESLH-2007-09833/Ym-23, ESAVI 2010-
04178/Ym-23 and ESAVI/7290/04.10.03/2012). The dogs 
were housed according to European Union guidelines 
in groups in indoor pens with access to outdoor runs. 
The indoor environmental temperature was maintained 
between 15 and 24  °C. The dogs were exposed to both 
natural and artificial light (from 7:00 to 16:00). They 
were fed a standard commercial diet and were evalu-
ated as healthy based on history, physical examination, 
a complete blood count, serum biochemistry, and fecal 
examination. Intestinal mucosal samples were collected 
from the duodenum, ileum, and colon (n = 18, each, and 
cecum (n = 6), snap-frozen in liquid nitrogen, and stored 
at − 80 °C for MMP-2 and -9 determination.
For canine patients, the inclusion criteria were chronic 
gastrointestinal signs such as vomiting, diarrhea, tenes-
mus, hematochezia, and/or weight loss lasting longer 
than 3  weeks. Diagnostic tests were performed on each 
dog to exclude underlying infectious or extraintestinal 
disorders, which included a complete blood count, serum 
biochemical analysis, fecal examination for parasites, 
abdominal ultrasound, and gastroduodenoscopy/colo-
noscopy with biopsy. The diagnosis of chronic enteropa-
thy (CE) was based on clinical, laboratory, endoscopic, 
and histopathologic criteria [28, 29].
Clinical examinations of dogs with CE
The clinical severity of disease in dogs with CE was deter-
mined by the CIBDAI score at the time of entering the 
study and after treatment [30]. In brief, the CIBDAI score 
was evaluated using six prominent GI related signs (atti-
tude and activity, appetite, vomiting, stool consistency, 
stool frequency, and weight loss). These were scored 
based on their severity from 0 to 3. The total CIBDAI 
score represents the summation of all individual scores 
and was classified as insignificant (score 0–3), mild (score 
4–5), moderate (score 6–8), or severe (score ≥ 9). The 
clinical outcome of dogs with CE was determined based 
on their response to treatment and since not all included 
dogs developed diarrhea as a clinical sign, the type of CE 
was defined as FRE, ARE, SRE, and SNRE [3, 4].
Serum albumin concentration in dogs with CE
The concentration of serum albumin was measured in 
each dog with CE and an albumin level of < 20  g/L was 
considered to indicate hypoalbuminemia. The severity of 
hypoalbuminemia was classified with a score of 1 (15–
19.9 g/L), 2 (12–14.9 g/L), or 3 (< 12 g/L) [1].
Histological examinations
For histologic examination of canine patients and con-
trols, mucosal tissue samples collected from the intestine 
by endoscopy or necropsy were fixed in 4% formaldehyde 
solution in phosphate buffered saline, embedded in par-
affin, sectioned (3–5  µm), and stained with hematoxy-
lin and eosin (HE). The intestinal tissue samples were 
evaluated and scored by a single pathologist (PS) using 
the guidelines of the World Small Animal Veterinary 
Association (WSAVA) Gastrointestinal Standardiza-
tion Group [28, 29]. The pathologist was blinded to the 
results of clinical and laboratory examinations, as well as 
the mucosal MMP-2 and -9 activities of each case. The 
severity of histological changes in different segments of 
the intestine was evaluated and scored as 0 = normal, 
1 = mild, 2 = moderate, or 3 = severe according to the 
WSAVA standardization guidelines. The total histologi-
cal change score, representing the sum of morphologic 
and inflammatory scores, was classified as insignificant 
(score 0–4), mild (score 5–9), moderate (score 10–14), 
severe (score 15–19), or very severe (score ≥ 20). Ileal and 
cecal biopsies were scored using the guidelines provided 
for the interpretation of duodenal and colonic biopsies 
due to the lack of specific templates for these intestinal 
parts in the guidelines of the WSAVA Gastrointestinal 
Standardization Group.
Gelatin zymography
In control dogs, the intestinal mucosa was separated 
from the underlying muscularis layer in the snap-frozen 
intestinal tissue samples and stored in − 80 °C for further 
analysis. Snap-frozen intestinal mucosal samples from 
healthy dogs and dogs with CE were homogenized using 
Precellys 24 ceramic beads (Bertin Technologies, Paris, 
France) in ice-cold extraction buffer at an extraction 
buffer to tissue ratio of 20:1, as previously described [26]. 
Samples were then centrifuged and the supernatants were 
collected and stored at − 80 °C for MMP-2 and -9 deter-
mination. Protein concentrations of the supernatants 
were measured with bicinchoninic acid protein assay rea-
gents (Pierce, Rockford, IL, USA). MMP-2 and MMP-9 
activities in supernatant were measured by gelatin 
zymography in mini-gels as previously described in detail 
[26]. Briefly, supernatants were separated by electropho-
resis in an 11% polyacrylamide gel impregnated with 
0.7 mg/mL of gelatin as a substrate. Each lane of the gel 
was loaded with 20 µL of supernatant containing 10 µg of 
total protein mixed with a 10 µL aliquot of loading buffer. 
After electrophoresis, the gels were first soaked in rena-
turing buffer (2.5% Triton X-100) and then in zymogram 
developing buffer (50 mM Tris Base, pH 7.5, containing 
200  mM NaCl, 5  mM  CaCl2.2H2O, and 0.02% Brilj-35). 
They were then incubated for 18  h at 37  °C and were 
finally stained. Zymogram developing buffer contains 
divalent metal cations, which are required for enzymatic 
activation of both the pro and active enzymes. The areas 
of proteinase activity were visualized as clear bands by 
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washing the gels with distilled water. As a control, each 
gel was loaded with diluted (1:600) recombinant human 
MMP-2 (9 μL) and -9 (8 μL) (R&D Systems, Minneapolis, 
MN, USA), respectively. The activities of pro- and active 
MMP-2 and -9 for each sample were expressed in arbi-
trary units (AU) related to the level of pro-MMP-2 of the 
positive-control standard loaded on each gel. Each band’s 
activity was reported as the mean of two different meas-
urements of the same sample due to the duplication of 
each sample in the gel.
Statistical analysis
Data are presented as the number (and percentage) of 
samples positive for MMP-2 and -9 or the median (range) 
of their activities, as appropriate. The differences in pro- 
and active MMP-2 and -9 positive samples in the duo-
denum, ileum, colon, and cecum between dogs with CE 
and healthy dogs were analyzed using Fisher’s exact test. 
Associations of the CIBDAI score and pro- and active 
MMP-2 and -9 activities were evaluated using Spear-
man’s correlation test. The same test was used to analyze 
the correlation between hypoalbuminemia and pro- and 
active MMP-2 and -9 activities in dogs with CE. The 
Kruskal–Wallis test was used to analyze the association 
between pro- and active MMP-2 and -9 activities and 
histological changes and the clinical outcome (FRE, ARE, 
SRE, and SNRE) in dogs with CE. P values < 0.05 were 
considered statistically significant. All statistical analyses 
were performed using SAS 9.3 statistical software (SAS 
Institute Inc., Cary, NC, USA).
Results
Demographics of dogs with CE and healthy dogs
The median age (range) of dogs with CE and healthy dogs 
was 5 years (1–13 years) and 10.5 (6–13), respectively. In 
the CE group, 15 dogs were intact males, 11 dogs were 
castrated males, 5 dogs were intact females, and 9 dogs 
were spayed females. In the healthy Beagle control group, 
8 dogs were intact males and 10 dogs were intact females. 
The breeds of dogs with CE were mixed breed (6), Rott-
weiler (2), German Shepherd dog (2), Shetland Sheepdog 
(2), Parson Russell Terrier (2), Rough Collie (2), Standard 
Poodle (2), and one each of the following: Alaskan Mala-
mute, Bichon Frise, Border Terrier, Chow Chow, Dalma-
tian, English Bulldog, Golden Retriever, Havanese, Irish 
Terrier, Jack Russell Terrier, Long-haired Dachshund, 
Mudi, Norwegian Lundehund, Rhodesian Ridgeback, 
Siberian Husky, Silky Terrier, Smooth Collie, Spanish 
Water Dog, Staffordshire Bull Terrier, Toy Poodle, West 
Highland White Terrier, and White Shepherd dog.
Of the 52 dogs with chronic GI signs, 12 dogs needed 
to be excluded from further analysis. Four dogs had pri-
mary esophageal disorders, and one dog was positive for 
Giardia sp. on fecal examination. Seven dogs had gastro-
intestinal neoplasia (3 gastric adenocarcinoma, 2 lym-
phoma, 1 rectal adenocarcinoma, and 1 rectal plasma 
cell tumor). Finally, 40 dogs with CE were included in the 
study analysis. Gastroduodenoscopy was performed in 25 
dogs, gastroduodenoscopy and colonoscopy in 10 dogs, 
and only colonoscopy in five dogs. During the endoscopic 
examinations, a total of 68 intestinal mucosal biopsies 
were collected from four different parts of the intestine 
[duodenum (n = 35), ileum (n = 12), colon (n = 15), and 
cecum (n = 6)] (Fig. 1). The flow diagram in Fig. 1 shows 
the group distribution and inclusion/exclusion criteria of 
all dogs enrolled in the study.
Mucosal MMP‑2 and ‑9 activities
The zymographic analyses revealed that gelatinolytic 
activities in positive samples were at the same molecular 
weights as the positive control bands of pro- and active 
MMP-2 and -9, and were therefore considered to repre-
sent canine pro- and active MMP-2 and -9 (Fig. 2). The 
median and range of mucosal pro- and active MMP-2 
Fig. 1 Flow diagram displaying inclusion/exclusion criteria and group distribution of all dogs enrolled in the study. CE chronic enteropathies
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and -9 activities in each intestinal segment in dogs with 
CE and healthy dogs are presented in Table 1.
In the duodenum, dogs with CE compared to healthy 
dogs had a significantly higher number (and percent-
age) of samples positive for mucosal pro-MMP-2 (32/35 
[91.4%] vs. 3/18 [16.7%]; P < 0.0001), active MMP-2 
(10/35 [28.6%] vs. 0/18 [0%]; P = 0.011), and pro MMP-9 
(34/35 [97.1%] vs. 10/18 [55.6%]; P = 0.0004) (Fig. 3). For 
active MMP-9, two positive samples were recorded in 
dogs with CE compared to none in healthy dogs, but this 
difference was not significant (Fig. 3). None of the intes-
tinal mucosal samples in healthy dogs showed gelatino-
lytic activity corresponding to the control bands of active 
MMP-2 and -9.
In the ileum, dogs with CE compared to healthy dogs 
had significantly higher numbers (and percentage) of 
samples positive for mucosal pro-MMP-2 (11/12 [91.7%] 
vs. 6/18 [33.3%]; P = 0.002) and active MMP-2 (4/12 
[33.3%] vs. 0/18 [0%]; P = 0.018; Fig.  3). For pro- and 
active MMP-9, dogs with CE had more positive samples 
compared to healthy dogs, but the differences were not 
significant (Fig. 3).
In the colon, dogs with CE compared to healthy dogs 
had a significantly higher number (and percentage) of 
samples positive for mucosal pro-MMP-2 (13/15 [86.7%] 
vs. 3/18 [16.7%]; P < 0.0001), active MMP-2 (7/15 [46.7%] 
vs. 0/18 [0%]; P = 0.002), and pro-MMP-9 (15/15 [100%] 
vs. 8/18 [44.4%]; P = 0.001, Fig. 3). However, in dogs with 
CE, only one had active MMP-9-positive samples com-
pared to healthy dogs with none (Fig. 3).
In the cecum, despite a higher percentage of samples 
positive for pro- and active MMP-2 and -9 in dogs with 
CE compared to healthy dogs, the differences between 
them did not reach statistical significance (Fig. 3).
Mucosal pro‑ and active MMP‑2 and ‑9 activities 
and histological changes
In the ileum, pro-MMP-2 activities were significantly 
higher in mucosal samples with a normal epithelium (P 
= 0.032) and with no neutrophilic infiltration (P = 0.034). 
Fig. 2 Representative zymogram from intestinal mucosa samples. Recombinant human pro- and active MMP-2 (lane 2) and -9 (lane 1), pro- and 
active MMP-2 and -9 positive samples in dogs with CE (lanes 3–4), pro-MMP-2 and -9 positive samples in dogs with CE (lanes 5–6), and a healthy 
dog (lane 7)
Table 1 Mucosal pro- and active MMP-2 and -9 activities in dogs with CE and healthy dogs
Pro- and active MMP-2 and -9 activities were measured in the mucosal samples from duodenum, ileum, colon, and cecum of dogs with CE and healthy dogs
AU arbitrary units; CE chronic enteropathies; Pro pro-enzyme
Intestinal part  Group Activity
Pro MMP‑2 (AU) median 
(range)
Active MMP‑2 (AU) 
median (range)
Pro MMP‑9 (AU) median 
(range)
Active MMP‑9 (AU) 
median (range)
Duodenum Dogs with CE (n = 35) 0.01 (0–1.66) 0 (0–0.02) 0.06 (0–3.86) 0 (0–0.21)
Healthy dogs (n = 18) 0 (0–0.64) 0 (0–0) 0.03 (0–3.32) 0 (0–0)
Ileum Dogs with CE (n = 12) 0.02 (0–0.83) 0 (0–0.01) 0.06 (0–0.5) 0 (0–0.28)
Healthy dogs (n = 18) 0 (0–0.52) 0 (0–0) 0.03 (0–0.45) 0 (0–0)
Colon Dogs with CE (n = 15) 0.03 (0–0.55) 0 (0–0.05) 0.07 (0.02–0.92) 0 (0–0.04)
Healthy dogs (n = 18) 0 (0–0.64) 0 (0–0) 0 (0–0.79) 0 (0–0)
Cecum Dogs with CE (n = 6) 0.0 (0.01–1.48) 0 (0–0.01) 0.09 (0.02–0.59) 0.005 (0–0.05)
Healthy dogs (n = 6) 0 (0–0.3) 0 (0–0) 0.18 (0–0.82) 0 (0–0)
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There was a significant positive association between the 
active MMP-2 activities and the severity of eosinophilic 
infiltration in cecal samples (P = 0.034). In addition, the 
association of active MMP-9 activities with the severity 
of neutrophilic infiltration in the duodenum (P = 0.040), 
and the severity of eosinophilic infiltration in the cecum 
(P = 0.037) were positive and significant. Active MMP-9 
activities were also significantly higher in cecal samples 
with normal lamina propria lymphocyte/plasma cell 
scores (P = 0.049).
Mucosal pro‑ and active MMP‑2 and ‑9 activities in relation 
to the CIBDAI and the clinical outcome
It was only possible to record the CIBDAI score before 
and after treatment in 30 out of 40 dogs with CE. The 
CIBDAI score before and after treatment was based on 
either available scores taken by the clinician in charge 
before and after the treatment (in 13/30 and 5/30 of dogs, 
respectively) or retrospectively calculated by the inves-
tigators (in 17/30 and 25/30 of dogs, respectively) from 
information in the clinical history (before the treatment) 
and from telephone interviews with the owners (after the 
treatment). Based on the response to treatment, the out-
comes of 30 dogs with CE were classified as follows: 10 
dogs with FRE, 4 dogs with ARE, 13 dogs with SRE, and 3 
dogs with SNRE. For pro- and active MMP-2 and -9, only 
active MMP-9 activities in the ileal mucosa had a strong 
positive correlation with the CIBDAI score before treat-
ment in dogs with CE (r = 0.71, P = 0.023). In dogs with 
CE, we did not find a significant association between the 
mucosal pro- and active MMP-2 and -9 activities and the 
clinical outcome in each intestinal segment.
Steroid non-responsive dogs (SNRE, n = 3) either died 
or were euthanized due to severe clinical signs. When 
comparing duodenal samples, the median (range) of the 
CIBDAI score before treatment was higher in SNRE dogs 
(n = 3) than in SRE dogs (n = 12) (7 [4–7] vs. 4.5 [0–7]). 
Hypoalbuminemia (< 20  g/L) was present in one SNRE 
and two SRE dogs. The median (range) of the total his-
tological change score was slightly higher for SNRE 
dogs than SRE dogs (7 [5–7] vs. 6 [1–11]). The median 
(range) of the pro- and active MMP-2 and -9 activities 
in the duodenal mucosa of SNRE dogs compared to SRE 
dogs were as follows: pro-MMP-2 (0.01 [0–0.02] AU vs. 
0.01 [0–1.66] AU), active MMP-2 (0 [0–0.01] AU vs. 0 
[0–0.01] AU), pro-MMP-9 (0.07 [0.02–0.16] AU vs. 0.09 
[0–3.86] AU), and active MMP-9 (0 [0–0.21] AU vs. 0 
[0–0] AU. The number of SNRE dogs was too low for sta-
tistical analysis other than descriptive comparison.
Fig. 3 Intestinal mucosal pro- and active MMP-2 and -9 activities in CE dogs and healthy dogs. This graph shows the presence of samples positive 
for pro- and active MMP-2 and -9 in the mucosa of duodenum (a), ileum (b), colon (c), and cecum (d) of dogs with CE and healthy dogs. P values 
are based on the comparison of pro- and active MMP-2 and-9 activities in the different part of the intestine of dogs with CE versus healthy dogs
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Mucosal pro‑ and active MMP‑2 and‑9 activities in relation 
to hypoalbuminemia in dogs with CE
In this study, 36 dogs out of 40 (90%) had a serum albu-
min level of > 20 g/L, with a median (range) of 32.65 g/L 
(24.9–39  g/L). A total of 4 out of 40 dogs (10%) had 
serum albumin concentrations of < 20  g/L (median 
12.2  g/L; range 11–13  g/L), with a hypoalbuminemia 
severity scores of 2 for two dogs and of 3 for another two 
[1]. Duodenal biopsy samples were taken from the four 
hypoalbuminemic CE dogs, and the correlations between 
mucosal pro- and active MMP-2 and-9 activities and 
hypoalbuminemia were evaluated. However, there was 
no significant correlation between pro-MMP-2 or active 
MMP-9 activities in the duodenal mucosa and hypoalbu-
minemia in dogs with CE. In hypoalbuminemic dogs with 
CE, compared to normoalbuminemic dogs with CE, the 
number (percentage) of positive samples in the duodenal 
mucosal was as follows: pro-MMP-2 (3/4 [75%] vs. 29/31 
[93.5%]), active MMP-2 (1/4 [25%] vs. 9/31 [29%], pro-
MMP-9 (3/4 [75%] vs. 31/31 [100%]), and active MMP-9 
(1/4 [25%] vs. 1/31 [3.2%]). The median (range) of the 
pro- and active MMP-2 and -9 activities in the duodenal 
mucosa of hypoalbuminemic dogs with CE compared to 
normoalbuminemic dogs with CE was as follows: pro-
MMP-2 (0.01 [0–0.017] AU vs. 0.01 [0–1.66] AU), active 
MMP-2 (0 [0–0.01] AU vs. 0 [0–0.02] AU), pro-MMP-9 
(0.14 [0–0.74] AU vs. 0.05 [0.01–3.86] AU), and active 
MMP-9 (0 [0–0.21] AU vs. 0 [0–0.1] AU.
Discussion
This study is the first to report mucosal MMP-2 and -9 
activities in the intestine of dogs with CE. The number 
of samples positive for pro- and active MMP-2 and pro-
MMP-9 was higher in the mucosa of dogs with CE com-
pared to healthy dogs in all intestinal segments when 
determined using gelatin zymography. Similar findings 
were also reported for active MMP-2 and pro-MMP-9 
in the colonic mucosa of humans with IBD compared to 
healthy controls [20]. A significantly higher percentage 
of colonic mucosal samples in dogs with CE had pro-
MMP-2 activity compared to healthy dogs (86.7% vs. 
16.7%). However, the percentage of samples with colonic 
mucosal pro-MMP-2 activity was the same in human 
patients with IBD and healthy controls, and activity was 
detected in 80% of the samples [20]. Active MMP-2 was 
detected in 46.7% of the colonic samples of dogs with CE. 
However, no activity was found in colonic mucosal sam-
ples of healthy dogs. Similarly to our findings, Baugh et al. 
[20] did not detect active MMP-2 activities in the colonic 
mucosa of healthy humans. However, they found active 
MMP-2 activities in 35% of samples in humans with IBD. 
Under normal conditions, MMP-2 is believed to par-
ticipate in the maintenance of collagen homeostasis and 
intestinal tissue remodeling. In human IBD, MMP-2 has 
been reported to contribute to ECM remodeling and the 
degradation of basal membrane type IV collagen, leading 
to intestinal ulceration, epithelial damage, and/or fistula 
formation [12, 15, 22–24]. It appears that intestinal tis-
sue turnover is increased during intestinal inflammation, 
tissue destruction, and healing processes, and demands 
greater MMP-2 activities in human IBD [15]. In contrast, 
it has been reported that MMP-2 plays a protective role 
against tissue damage, possibly through the regulation 
of epithelial barrier function, in an MMP-2 knockout 
mouse model of IBD [10, 13, 14]. In our study, it appears 
that having higher activities of pro- and active MMP-2 
in dogs with CE indicates the possible involvement of 
this enzyme in the pathogenesis of canine chronic enter-
opathies. In addition, we showed that the samples with 
higher pro-MMP-2 activities have an association with a 
normal epithelium and lamina propria without neutro-
phils in the ileum. Similarly to the study on an MMP-2 
knockout mouse model of IBD, it is possible that MMP-2 
has a protective role against tissue damage through the 
regulation of epithelial barrier function in dogs; however, 
more research is needed to clarify the role of MMP-2 in 
canine CE.
Mucosal pro-MMP-9 was detected in more than 90% of 
the samples in the intestinal segments of dogs with CE, 
while this form of enzyme was detected in 33–61% of the 
intestinal mucosal samples of healthy dogs. Therefore, 
pro-MMP-9 activities are elevated in dogs with CE com-
pared to healthy dogs, which is similar to the findings of 
Baugh et  al. [20] in humans with IBD. In our study, we 
did not detect the active form of MMP-9 in the mucosa 
of healthy dogs. Similar findings were also reported in 
the colonic mucosa of healthy humans [20]. In dogs with 
CE, the active form of MMP-9 was detected in 5.7, 25, 
5.6, and 50% of duodenal, ileal, colonic, and cecal sam-
ples, respectively. In the duodenal and cecal samples, we 
also found a positive and significant association between 
active MMP-9 activities and the severity of lamina pro-
pria neutrophilic and eosinophilic infiltration, with these 
cells being proposed as sources of MMP-9. In compari-
son to human IBD, the percentage of active MMP-9-pos-
itive samples in the colon of dogs with CE was much 
lower (55% vs. 5.6%) [20]. This difference could be due 
to the different pathophysiology of canine and human 
chronic colitis. A higher number of infiltrated neutro-
phils and more ulcerative lesions in humans with chronic 
colitis could be the possible reasons for the higher 
active MMP-9 activities in humans [15]. In future stud-
ies, immunohistochemistry should also be included to 
assess the localization of MMP-2 and -9 in the intestinal 
mucosa and their correlation with intestinal pathologies 
in dogs.
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We found a positive correlation between active MMP-9 
activities in the ileal mucosa and the CIBDAI score 
before treatment in dogs with CE, which is similar to the 
relationship between mucosal MMP-9 and the disease 
activity index in a rat model of colitis [31], and between 
fecal MMP-9 and clinical activities of ulcerative colitis in 
humans [32]. However, due to the low number of active 
MMP-9-positive samples (n = 3) in the ileal samples 
of dogs with CE in our study, the results should not be 
over-interpreted.
The association between an aberrant intestinal expres-
sion of MMP-2 and -9 and human IBD is now well estab-
lished [33]. MMP-2 and -9 have been investigated as 
biomarkers and diagnostic tool for human IBD. The level 
of fecal MMP-9 in UC patients correlates with disease 
activity and has recently been proposed as a biomarker 
of the disease. By measuring fecal MMP-9 levels, it was 
possible to distinguish UC from diarrhea predominant 
irritable bowel syndrome with 85% sensitivity and 100% 
specificity [34]. Serum level of MMP-9 have also been 
shown as a potential tool in the prediction of CD activity 
status in children [35]. In addition, MMP-2 and MMP-9 
levels in urine of pediatric patients with IBD have been 
reported as useful novel non-invasive biomarkers to 
predict CD and UC independently in children [33]. 
Our study is the first to demonstrate an upregulation of 
mucosal pro- and active MMP-2 and pro-MMP-9 in the 
intestine of dogs with CE. This is a promising indication 
that MMPs play a role in canine CE with the potential of 
being used as biomarkers of active disease and disease 
severity. In the present study, however, we did not find a 
significant association between mucosal MMP-2 and -9 
activities and the type of clinical outcome in dogs with 
CE which could be due to the low number of dogs with 
a certain clinical outcome (especially SNRE dogs, n = 3). 
In addition, the comparison between intestinal segments 
led to rather low case numbers when assessing the asso-
ciation between mucosal MMP-2 and -9 activities with 
the type of clinical outcome. Further studies with suf-
ficient number of canine patients in each types of CE is 
needed to evaluate the relationship between MMP-2 and 
-9 activities and canine CE subtypes. MMP expression in 
the intestine or elsewhere in the body, e.g. serum or feces, 
may in the future help in properly differentiating disease 
subtypes and severity, and to enable tailored treatment 
choices for individuals.
A unique therapeutic option for human IBD is target-
ing MMPs which has been investigated in animal models 
of IBD. Inhibition of MMPs with non-selective inhibitors 
(e.g. Marimastat, Batimastat) has been shown to reduce 
mucosal damage and colitis induced by dextran sodium 
sulfate (DSS) in animal models [33]. However, the devel-
opment of MMP inhibitors in humans has been limited 
by their poor selectivity [33]. To target MMPs, mono-
clonal antibodies against MMP-2 and MMP-9 have been 
developed and tested on murine models of IBD. These 
antibodies were significantly reducing the severity of the 
DSS induced colitis in mice [33, 36]. However, due to 
the myriad roles of MMPs in  vivo and their ubiquitous 
expression throughout the body, using monoclonal anti-
bodies remains a serious concern and a barrier to their 
current therapeutic use in human IBD [33]. Whether tar-
geting MMPs using monoclonal antibodies in canine CE 
patients is beneficial for CE treatment is not known yet 
and needs to be studied.
It has been shown that treatment of human IBD with 
immunosuppressive medications could reduce the levels 
of MMPs in the intestinal mucosa and serum. Makitalo 
et  al. [37] showed in people that the treatment of CD 
patients with anti-TNF-α therapy (infliximab or adali-
mumab) or with corticosteroids and other immunosup-
pressive drugs (methotrexate or azathioprine) decreased 
stromal MMP-9 and epithelial MMP-7 as assessed by 
immunohistochemistry methods. However, there are dif-
ferent reports regarding the response of MMP-9 to ther-
apy in serum. Gao et al. [38] reported that serum levels 
of MMP-9 decrease in adults in response to infliximab 
therapy; however, Makitalo et  al. [39] reported no sig-
nificant changes in serum MMP-9 levels after therapy. In 
mice, mangiferin, a bioactive compound of the mango, 
attenuated DSS induced colitis through directly reducing 
the activity of mucosal TNF-α and MMP-9 [40]. Future 
studies in CE dogs should be planned as treatment follow 
up studies with repeated biopsies to evaluate the treat-
ment effects of different medication especially immuno-
suppressive drugs such as prednisolone on the intestinal 
mucosal MMP-2 and -9 activities.
We did not find significant correlations between 
pro- and active MMP-2 and -9 activities in the duo-
denal mucosa and hypoalbuminemia in dogs with CE. 
Since only 10% (4/40) of the dogs had hypoalbumine-
mia (< 20  g/L), the number of samples was too low for 
an appropriate power of analysis and it could be the rea-
son why we did not find significant correlations between 
MMP2 and 9 activities. In humans, to our knowledge, 
there has been so far no report studying MMP-2 and -9 
activities in patients with protein losing enteropathies. In 
future prospective studies, the necessary number of cases 
of CE dogs with hypoalbuminemia should be prospec-
tively estimated by using power analysis, for which the 
data of the current study are helpful. In the future, it will 
also be necessary to focus more on advanced cases with 
intestinal protein loss, a patient group that was underrep-
resented in this study and also looking for other MMPs. 
Another limitation of our study is that the cobalamin and 
folate concentrations were not measured in a sufficient 
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number of dogs with CE to allow statistical analysis. 
Therefore, future prospective studies need to include a 
variety of laboratory data to assess possible associations/
correlations.
Conclusions
This is the first study to demonstrate that mucosal pro- 
and active MMP-2 and pro-MMP-9 are upregulated 
in the intestine of dogs with CE compared to healthy 
dogs. Compared to humans with IBD, the active form of 
MMP-9 has been detected in a rather small number of 
canine patients, which could be due to the low number of 
granulocytes found in the intestinal mucosa of dogs with 
CE. The results provide supporting evidence for the pos-
sible involvement of MMP-2 and -9 in the pathogenesis of 
canine CE. Further research is needed to assess the local-
ization of MMP-2 and -9 in the canine intestinal mucosa, 
their presence and activity level in advanced CE with 
intestinal protein loss, and their relationship with other 
inflammatory markers in canine chronic enteropathies. 
Furthermore, their activities in fecal samples should be 
determined to examine their possible usefulness as non-
invasive biomarkers of intestinal inflammation.
Abbreviations
ARD: antibiotic-responsive diarrhea; ARE: antibiotic-responsive enteropathy; 
AU: arbitrary unit; CD: Crohn’s disease; CE: chronic enteropathy; CIBDAI: canine 
inflammatory bowel disease activity index; cTLI: canine trypsin-like immuno-
reactivity; DSS: dextran sodium sulfate; ECM: extracellular matrix; FRD: food-
responsive diarrhea; FRE: food-responsive enteropathy; GI: gastrointestinal; 
HE: hematoxylin and eosin; IBD: inflammatory bowel disease; MMPs: matrix 
metalloproteinases; SRD: steroid-responsive diarrhea; SRE: steroid-responsive 
enteropathy; SNRD: steroid non-responsive diarrhea; SNRE: steroid non-
responsive enteropathy; TNF-α: tumor necrosis factor-alpha; UC: ulcerative 
colitis; WSAVA: World Small Animal Veterinary Association.
Authors’ contributions
MH, MMR, LM, and TS conceived the study design. SK performed sample 
collection. MH measured MMP-2 and-9 activities. PS performed histology 
diagnosis. All authors read and approved the final manuscript.
Author details
1 Department of Equine and Small Animal Medicine, Faculty of Veterinary 
Medicine, University of Helsinki, P.O. Box 57, (Viikintie 49), 00014 Helsinki, 
Finland. 2 Department of Clinical Sciences, Faculty of Veterinary Medicine, 
University of Tabriz, 5166616471 Tabriz, Iran. 3 Department of Veterinary 
Biosciences, Faculty of Veterinary Medicine, University of Helsinki, P.O. Box 66, 
(Agnes Sjöberginkatu 2), 00014 Helsinki, Finland. 4 Children’s Hospital, Helsinki 
University Central Hospital, University of Helsinki, P.O. Box 63, (Haartmaninkatu 
8), 00014 Helsinki, Finland. 
Acknowledgements
The authors would like to thank Jouni Junnila and Tommi Pesonen, 4Pharma, 
Finland, for performing statistical analysis of the data and Laura Parikka for 
technical assistance.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The samples from healthy control dogs were collected during post-mortem 
examinations after finishing unrelated studies. These studies were ethi-
cally approved by the Finnish National Animal Experiment Board (study 
license No. ESLH-2007-09833/Ym-23, ESAVI 2010-04178/Ym-23, and 
ESAVI/7290/04.10.03/2012). For clinical trial involving dogs with chronic 
enteropathies, ethical approval was granted by the same authority under the 
license numbers ESAVI/6973/04.10.03/2011 and ESAVI/10384/04.10.07/2014. 
Informed owner consent was obtained at the time the dogs were enrolled to 
perform gastroduodenoscopy and/or colonoscopy.
Funding
This work was supported by the Finnish Veterinary Foundation, Finland 
(Grant Decision Year: 2013, 2014, 2015) and the Doctoral Program in Clinical 
Veterinary Medicine, University of Helsinki, Helsinki, Finland (Grant Decision 
Year: 2013, 2014). The funders had no role in study design, data collection and 
analysis, decision to publish, or preparation of the manuscript.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 20 September 2017   Accepted: 8 March 2018
References
 1. Allenspach K, Wieland B, Grone A, Gaschen F. Chronic enteropathies in 
dogs: evaluation of risk factors for negative outcome. J Vet Intern Med. 
2007;21:700–8.
 2. Wennogle SA, Priestnall SL, Webb CB. Histopathologic characteristics 
of intestinal biopsy samples from dogs with chronic inflammatory 
enteropathy with and without hypoalbuminemia. J Vet Intern Med. 
2017;31:371–6.
 3. Simpson KW, Jergens AE. Pitfalls and progress in the diagnosis and man-
agement of canine inflammatory bowel disease. Vet Clin North Am Small 
Anim Pract. 2011;41(2):381–98.
 4. Dandrieux JR. Inflammatory bowel disease versus chronic enteropathy in 
dogs: are they one and the same? J Small Anim Pract. 2016;57:589–99.
 5. German AJ, Hall EJ, Day N. Chronic intestinal inflammation and intestinal 
disease in dogs. J Vet Intern Med. 2003;17:8–20.
 6. Jergens AE, Simpson KW. Inflammatory bowel disease in veterinary 
medicine. Front Biosci (Elite Ed). 2012;4:1404–19.
 7. Jergens AE, Sonea IM, O’Connor AM, Kauffman LK, Grozdanic SD, Acker-
mann MR, et al. Intestinal cytokine mRNA expression in canine inflam-
matory bowel disease: a meta-analysis with critical appraisal. Comp Med. 
2009;59:153–62.
 8. Cassmann E, White R, Atherly T, Wang C, Sun Y, Khoda S, et al. Alterations 
of the ileal and colonic mucosal microbiota in canine chronic enteropa-
thies. PLoS ONE. 2016;11:e0147321.
 9. Schmitz S, Glanemann B, Garden OA, Brooks H, Chang YM, Werling D, 
et al. A prospective, randomized, blinded, placebo-controlled pilot study 
on the effect of Enterococcus faecium on clinical activity and intestinal 
gene expression in canine food-responsive chronic enteropathy. J Vet 
Intern Med. 2015;29:533–43.
 10. Ravi A, Garg P, Sitaraman SV. Matrix metalloproteinases in inflammatory 
bowel disease: boon or a bane? Inflamm Bowel Dis. 2007;13:97–107.
 11. Naito Y, Yoshikawa T. Role of matrix metalloproteinases in inflammatory 
bowel disease. Mol Aspects Med. 2005;26:379–90.
 12. O’Sullivan S, Gilmer JF, Medina C. Matrix metalloproteinases in inflamma-
tory bowel disease: an update. Mediators Inflamm. 2015;2015:964131.
 13. Garg P, Rojas M, Ravi A, Bockbrader K, Epstein S, Vijay-Kumar M, et al. 
Selective ablation of matrix metalloproteinase-2 exacerbates experimen-
tal colitis: contrasting role of gelatinases in the pathogenesis of colitis. J 
Immunol. 2006;177:4103–12.
Page 10 of 10Hanifeh et al. Acta Vet Scand  (2018) 60:16 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 14. Garg P, Vijay-Kumar M, Wang LX, Gewirtz AT, Merlin D, Sitaraman SV. 
Matrix metalloproteinase-9-mediated tissue injury overrides the protec-
tive effect of matrix metalloproteinase-2 during colitis. Am J Physiol 
Gastrointest Liver Physiol. 2009;296:G175–84.
 15. Gao Q, Meijer MJW, Kubben F, Sier CFM, Kruidenier L, van Duijn W, et al. 
Expression of matrix metalloproteinases-2 and-9 in intestinal tissue of 
patients with inflammatory bowel diseases. Dig Liver Dis. 2005;37:584–92.
 16. Kirkegaard T, Hansen A, Bruun E, Brynskov J. Expression and localisation 
of matrix metalloproteinases and their natural inhibitors in fistulae of 
patients with Crohn’s disease. Gut. 2004;53:701–9.
 17. Hogan SP. Functional role of eosinophils in gastrointestinal inflammation. 
Immunol Allergy Clin North Am. 2009;29:129–40.
 18. Kim JH, Lee SY, Bak SM, Suh IB, Shin C, Shim JJ, et al. Effects of matrix 
metalloproteinase inhibitor on LPS-induced goblet cell metaplasia. Am J 
Physiol Lung Cell Mol Physiol. 2004;287:L127–33.
 19. Lubbe WJ, Zhou ZY, Fu W, Zuzga D, Schulz S, Fridman R, et al. Tumor 
epithelial cell matrix metalloproteinase 9 is a target for antimetastatic 
therapy in colorectal cancer. Clin Cancer Res. 2006;12:1876–82.
 20. Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, Lobo AJ, et al. 
Matrix metalloproteinase levels are elevated in inflammatory bowel 
disease. Gastroenterology. 1999;117:814–22.
 21. Makitalo L, Kolho KL, Karikoski R, Anthoni H, Saarialho-Kere U. Expres-
sion profiles of matrix metalloproteinases and their inhibitors in colonic 
inflammation related to pediatric inflammatory bowel disease. Scand J 
Gastroenterol. 2010;45:862–71.
 22. Matsuno K, Adachi Y, Yamamoto H, Goto A, Arimura Y, Endo T, et al. The 
expression of matrix metalloproteinase matrilysin indicates the degree of 
inflammation in ulcerative colitis. J Gastroenterol. 2003;38:348–54.
 23. McKaig BC, McWilliams D, Watson SA, Mahida YR. Expression and regula-
tion of tissue inhibitor of metalloproteinase-1 and matrix metalloprotein-
ases by intestinal myofibroblasts in inflammatory bowel disease. Am J 
Pathol. 2003;162:1355–60.
 24. Stallmach A, Chan CC, Ecker KW, Feifel G, Herbst H, Schuppan D, et al. 
Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis 
and ulcerative colitis. Gut. 2000;47:415–22.
 25. Castaneda FE, Walia B, Vijay-Kumar M, Patel NR, Roser S, Kolachala VL, 
et al. Targeted deletion of metalloproteinase 9 attenuates experimental 
colitis in mice: central role of epithelial-derived MMP. Gastroenterology. 
2005;129:1991–2008.
 26. Hanifeh M, Rajamaki MM, Makitalo L, Syrja P, Sankari S, Kilpinen S, et al. 
Identification of matrix metalloproteinase-2 and -9 activities within 
intestinal mucosa of clinically healthy beagle dogs. J Vet Med Sci. 
2014;76:1079–85.
 27. Wilke VL, Nettleton D, Wymore MJ, Gallup JM, Demirkale CY, Acker-
mann MR, et al. Gene expression in intestinal mucosal biopsy speci-
mens obtained from dogs with chronic enteropathy. Am J Vet Res. 
2012;73:1219–29.
 28. Day MJ, Bilzer T, Mansell J, Wilcock B, Hall EJ, Jergens A, et al. Histopatho-
logical standards for the diagnosis of gastrointestinal inflammation in 
endoscopic biopsy samples from the dog and cat: a report from the 
World Small Animal Veterinary Association Gastrointestinal Standardiza-
tion Group. J Comp Pathol. 2008;138(Suppl 1):S1–43.
 29. Washabau RJ, Day MJ, Willard MD, Hall EJ, Jergens AE, Mansell J, et al. 
Endoscopic, biopsy, and histopathologic guidelines for the evaluation of 
gastrointestinal inflammation in companion animals. J Vet Intern Med. 
2010;24:10–26.
 30. Jergens AE, Schreiner CA, Frank DE, Niyo Y, Ahrens FE, Eckersall PD, et al. A 
scoring index for disease activity in canine inflammatory bowel disease. J 
Vet Intern Med. 2003;17:291–7.
 31. Oliveira LG, Cunha AL, Duarte AC, Castanon MC, Chebli JM, Aguiar 
JA. Positive correlation between disease activity index and matrix 
metalloproteinases activity in a rat model of colitis. Arq Gastroenterol. 
2014;51:107–12.
 32. Farkas K, Sarodi Z, Balint A, Foldesi I, Tiszlavicz L, Szucs M, et al. The diag-
nostic value of a new fecal marker, matrix metalloprotease-9, in different 
types of inflammatory bowel diseases. J Crohn’s Colitis. 2015;9:231–7.
 33. O’Shea NR, Smith AM. Matrix metalloproteases role in bowel inflamma-
tion and inflammatory bowel disease: an up to date review. Inflamm 
Bowel Dis. 2014;20:2379–93.
 34. Dabritz J, Musci J, Foell D. Diagnostic utility of faecal biomarkers 
in patients with irritable bowel syndrome. World J Gastroenterol. 
2014;20:363–75.
 35. Kofla-Dlubacz A, Matusiewicz M, Krzystek-Korpacka M, Iwanczak B. Cor-
relation of MMP-3 and MMP-9 with Crohn’s disease activity in children. 
Dig Dis Sci. 2012;57:706–12.
 36. Sela-Passwell N, Kikkeri R, Dym O, Rozenberg H, Margalit R, Arad-Yellin R, 
et al. Antibodies targeting the catalytic zinc complex of activated matrix 
metalloproteinases show therapeutic potential. Nat Med. 2011;18:143–7.
 37. Makitalo L, Sipponen T, Karkkainen P, Kolho KL, Saarialho-Kere U. Changes 
in matrix metalloproteinase (MMP) and tissue inhibitors of metallopro-
teinases (TIMP) expression profile in Crohn’s disease after immunosup-
pressive treatment correlate with histological score and calprotectin 
values. Int J Colorectal Dis. 2009;24:1157–67.
 38. Gao Q, Meijer MJ, Schluter UG, van Hogezand RA, van der Zon JM, van 
den Berg M, et al. Infliximab treatment influences the serological expres-
sion of matrix metalloproteinase (MMP)-2 and -9 in Crohn’s disease. 
Inflamm Bowel Dis. 2007;13:693–702.
 39. Makitalo L, Rintamaki H, Tervahartiala T, Sorsa T, Kolho KL. Serum MMPs 
7-9 and their inhibitors during glucocorticoid and anti-TNF-alpha 
therapy in pediatric inflammatory bowel disease. Scand J Gastroenterol. 
2012;47:785–94.
 40. Somani S, Zambad S, Modi K. Mangiferin attenuates DSS colitis in 
mice: molecular docking and in vivo approach. Chem Biol Interact. 
2016;253:18–26.
